Physician profile
Angela Lin
NPI 1891234407
$3,902.55
in general payments reported to CMS, 2019-2025
11 companies · $1,104 in 2025
The $1,104 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $32.00 · 2021: $182 · 2022: $424 · 2023: $804 · 2024: $809 · 2025: $1,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,547 · Entertainment: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,546.92 |
| Entertainment | $170.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,439.54 | 2019-2025 | Acuvue |
| Coopervision INC. | $926.56 | 2023-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Bausch & Lomb Americas INC. | $304.17 | 2022-2025 | Infuse Multifocal, Infuse |
| Alcon Vision LLC | $262.56 | 2019-2024 | Clareon |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $221.96 | 2019-2021 | |
| Biotissue Holdings INC. | $205.54 | 2022-2025 | |
| Optos, INC. | $170.91 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Horizon Therapeutics Plc | $151.59 | 2023 | Tepezza |
| Spark Therapeutics, INC. | $104.17 | 2022 | |
| Oyster Point Pharma, INC. | $87.45 | 2023-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $28.10 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.